Cookies?
Library Header Image
LSE Research Online LSE Library Services

Promoting innovation while controlling cost: the UK’s approach to health technology assessment

Anderson, Michael ORCID: 0000-0002-8454-4640, Drummond, Michael, Taylor, David, Mcguire, Alistair, Carter, Paul and Mossialos, Elias (2022) Promoting innovation while controlling cost: the UK’s approach to health technology assessment. Health Policy, 126 (3). pp. 224-233. ISSN 0168-8510

[img] Text (Health Policy manuscript_17_01_clean) - Accepted Version
Registered users only
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (598kB) | Request a copy
[img] Text (1-s2.0-S0168851022000239-main) - Published Version
Available under License Creative Commons Attribution.

Download (581kB)

Identification Number: 10.1016/j.healthpol.2022.01.013

Abstract

New technologies, including pharmaceuticals and medical devices, can improve treatment options in healthcare but also bring concerns about rising healthcare costs. We undertake a narrative review of the United Kingdom's (UK) approach to appraising new health technologies. We find that the National Institute for Health and Care Excellence (NICE), Scottish Medicines Consortium (SMC) and All Wales Medicines Strategy Group (AWMSG) have contributed to the UK's robust and transparent approach towards the evaluation of new health technologies using the cost per QALY approach. However, there are limitations to this approach including several external benefits not captured, bias against less treatable diseases, and deciding the appropriate level of the threshold. NICE, SMC, and AWMSG have attempted to overcome some of these limitations by considering additional factors such as end-of-life criteria, highly specialised treatments, and populations that experience unmet need. Looking to the future, the advent of ‘personalised’ and ‘genomic’ medicine, will likely mean the UK has to accommodate an increasing number of ‘step-change’ and ‘highly specialised’ technologies as well as respond to changes in pharmaceutical licensing and increasing use of real-world evidence.

Item Type: Article
Official URL: https://www.sciencedirect.com/journal/health-polic...
Additional Information: © 2022 The Author(s)
Divisions: LSE Health
LSE
Health Policy
Subjects: R Medicine > RA Public aspects of medicine
Date Deposited: 01 Feb 2022 09:57
Last Modified: 30 Mar 2022 12:03
URI: http://eprints.lse.ac.uk/id/eprint/113587

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics